Specifically, higher NRG signature scores were observed in male patients, those with advanced tumor stages, those classified as T 3–4, individuals presenting with lymph node metastasis, and patients carrying KRAS or TP53 mutations. The gene discussed is KRAS; the disease is metastatic malignant neoplasm in the lymph nodes.